Neuroderm: Reiterating Buy Rating With Price Target=$49 (Update After Q4 Earnings And Annual Report)

NDRM

We listened to Neuroderm's Q4 earnings call and reviewed the annual report. The company announced successful phase 2 data from trial 006 testing ND0612 +oral standard of care therapy for the treatment of motor fluctuations in advanced Parkinson's disease, PD recently. The company plans to conduct...

We listened to Neuroderm's Q4 earnings call and reviewed the annual report. The company announced successful phase 2 data from trial 006 testing ND0612 +oral standard of care therapy for the treatment of motor fluctuations in advanced Parkinson's disease, PD recently. The company plans to conduct...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics